Search This Blog

Friday, April 17, 2026

Kura 44% response, 94% disease control for darlifarnib plus cabozantinib in clear cell renal cell carcinoma

 

Kura Oncology reports 44% response, 94% disease control for darlifarnib plus cabozantinib in cabozantinib-pretreated clear cell renal cell carcinoma

  • Preliminary subset results are from the FIT-001 trial in cabozantinib-pretreated clear cell renal cell carcinoma.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)